Is marketing deal with 5 links exclusive, or can the company still form other distribution relationships? Aside from the deal value ( 5 links), why not partner up with a company that sells vitamin/supplements vs an outfit that peddles electronics?
Outside of mice data, have there been any 1st in man trials with Niagin generating clinical efficacy results of compound?
If your watching level II trading its not a reliable gauge to design a strategy around. Volume will decide the velocity/direction of PPS and company progress the same. If volume dries up- traders walk off the job site. And if the fundies come short-longs go into mundane bear hibernation (no groundhog welcoming as fueled hyperbole meets up with operations/reality).
Are there any derm reports praising the non-surgical face-lift product vs promotions? And how long has skin-dulgence been marketed, and any negative claims or suits?
Will this company with decent earnings, receive a low-valuation, based on being perceived as a box maker?
Great YOY revenue growth. And wondering who loves this company and why?
11/21/2003 13:19:16 Bought 500 HANS @ 9
11/21/2003 13:19:16 Bought 300 HANS @ 8.94
Try owning MNST aka HANS at $8/10 year ago. EMAN could be a powerhouse too- if they meet their goals for production and are savvy in diversifying rapidly into burgeoning consumer markets. Still in test-flight$
Being gnostic in ones company risk/reward analysis is a better investor approach vs romanticism path.
With a 2.4% cover- shorts aren't inside illiquid stocks like EMAN. This is an investment where your money is well-timed. Instead, having your money is tied up waiting on a distant and moving target, climatic event. Shorts- wouldn't like the risk/reward prospects here. Profit-taking explains the activity in stock better.